Slide 1: SNT-4728 iRBD phase 2a trial preliminary results
SNT-4728 iRBD phase 2a trial preliminary results Webinar Gary Phillips, CEO 6th July 2026
Slide 2: Forward Looking Statement
FORWARD LOOKING STATEMENT This document contains These forward-looking forward-looking statements, statements are not guarantees including statements or predictions of future results, concerning Syntara’s future levels of performance, and financial position, plans, and the involve known and unknown
Slide 3: SNT-4728 Phase 2a Study – Webinar Participants
SNT-4728 Phase 2a Study – Webinar Participants Professor Simon Lewis Gary Phillips Jana Baskar Trial Principal Investigator CEO Chief Medical Officer • Neurologist sub-specialised in • More than 30 years of operational • 20+ years’ experience both in clinical degenerative diseases of the brain manag
Slide 4: iRBD and Parkinson's
iRBD AND Using a sleep disorder to target Parkinson’s. PARKINSON’S Early intervention to demonstrate neuroprotection – rather than late treatment when most neurons have already been KEY FACTS lost (for example in PD) – is where disease-modifying, • Patients with isolated REM sleep behaviour slowing
Slide 5: SNT-4728: Clinical Trial
SNT-4728: Study funded by Parkinson’s CLINICAL TRIAL UK Virtual Biotech and is being run at sites in Sydney, Australia and Oxford, UK Phase 2 multi-centre, placebo- controlled study assessing effect of SNT-4728 on brain inflammation in patients with iRBD • 40 patients (3:1 drug to placebo randomisat
Slide 6: Study Endpoints
STUDY ENDPOINTS Primary endpoint Secondary endpoints Exploratory endpoints • Changes observed in • Change in TSPO ligand • Changes in clinical TSPO ligand binding on binding on PET imaging measurements relevant to PET imaging in striato- across subcortical and iRBD from Baseline to cortical ROIs com
Slide 7: Baseline Characteristics and Exposure and Safety
BASELINE EXPOSURE AND CHARACTERISTICS SAFETY Study successfully recruited an In keeping with the excellent enriched iRBD population at high safety profile observed in prior risk for phenoconversion to Phase 2 studies, SNT-4728 was safe Parkinson’s and related diseases and well tolerated • Median age
Slide 8: Reduction in Inflammation
REDUCTION IN Binding Potential (BPND) P-value INFLAMMATION Putamen Mean at Mean at Mean change (Paired t- test) baseline 12 weeks Statistically significant Right 0.002918 -0.012073 -0.016 (0.033) 0.0145 reduction in brain inflammation observed unilaterally in the Left -0.001209 0.001692 0.003 (0.029
Slide 9: Next Steps in This Study
NEXT STEPS IN THIS STUDY Digital biomarkers Biological markers Data integration Exploratory endpoints measuring Exploratory endpoints measuring • AI-driven integration of imaging cognitive, motor function and inflammation and neurodegeneration data with liquid and digital actigraphy in the blood and
Slide 10: SNT-4728 iRBD phase 2a study; Key outcomes
SNT-4728 iRBD phase 2a study; Key outcomes • First interventional study to directly target neuroinflammation in patients with iRBD and interrogate the disease biology underlying patient progression to Parkinson’s disease. • Statistically significant reduction in brain inflammation was observed unila
Slide 11: Syntara Limited – Gary Phillips contact details
Syntara Limited ABN 75 082 811 630 Gary Phillips Chief Executive Officer www.syntaraTX.com.au gary.phillips@syntaraTX.com.au